In GBM, we observed that both cancer cell antigen release (step 1) and immune cell trafficking to tumors (step 4)—including the recruitment of CD4 T cells, Th22 cells, monocytes, neutrophils, and eosinophils—were significantly upregulated in the high TMED9 expression group. This evidence concerns the gene TMED9 and cancer.